Showing 8351-8360 of 9758 results for "".
- Coolibar Gets Gross To Prevent Skin Cancerhttps://practicaldermatology.com/news/coolibar-gets-gross-to-prevent-skin-cancer/2458206/Sun protective clothing and accessory maker Coolibar’s new skin cancer prevention and awareness campaign may make you sick, and that’s kind of the point. Called "Let's Get Gross," the new campaign will feature stories f
- Kourtney Kardashian's Fave Skincare Brand Rolls Out New Body Oil Collectionhttps://practicaldermatology.com/news/kourtney-kardashians-fave-skincare-brand-rolls-out-new-body-oil-collection/2458212/Manuka Doctor is launching their newest body oil collection --The Manuka Doctor 24K Gold & Manuka Honey. The brand, which boasts Kourtney Kardashian as their global ambassador, is rolling out the new collection in late April 2017. The bo
- RxPhoto Releases Updated HIPPA-Compliant Mobile Clinical Photography Apphttps://practicaldermatology.com/news/rxphoto-releases-updated-mobile-hippa-compliant-clinical-photo-app/2458213/RxPhoto has released version 3 of its mobile medical photography solution for medical practices and providers. Medical practices can now remain HIPAA compliant while using their mobile devices to securely capture, manage and share medical photos and videos.
- BioPharmX Completes Phase 2b Trial of BPX-01; Topline Results Coming Soonhttps://practicaldermatology.com/news/biopharmx-completes-phase-2b-trial-of-bpx-01-topline-results-coming-soon/2458217/BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017. The company now plans to announce topline data from the trial in the fi
- Study: Severe Psoriasis More Common in Menhttps://practicaldermatology.com/news/severe-psoriasis-more-common-in-men/2458235/Severe psoriasis predominantly affects men, according to a new study in the American Journal of Clinical Dermatology. In the study of 5,438 Swedish psoriasis patients, women had significantly (p<0.
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce
- A “C” Change: Introducing Exuviance's New Vitamin C Serum Capsuleshttps://practicaldermatology.com/news/a-c-change-introducing-exuviances-new-vitamin-c-serum-capsules/2458250/Coming this summer, Exuviance’s AF Vitamin C20 serum capsules promise maximum delivery of actives. Unlike many existing products, Exuviance AF Vitamin C20 Serum comes in capsule form. Other types of packaging expose vitamin C to light, air, o
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBShttps://practicaldermatology.com/news/rare-disease-breakthrough-new-treatment-may-reduce-blistering-in-ebs/2458255/In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annu
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill